In response to a variety of stimuli, human neutrophils undergo a respiratory burst in which oxygen is converted to superoxide (O2-), hydrogen peroxide, and hydroxyl radicals (or related radical species). While these agents generally serve a beneficial role in killing ingested microorganisms, they also can cause serious damage to normal tissues during inflammation. In addition, several human diseases are associated with failure to appropriately regulate oxygen radical production. In adult respiratory distress syndrome, pulmonary damage occurs due to excessive oxygen radical production while in chronic granulomatous disease (CGD), failure to produce these radicals leads to life-threatening infections. The studies proposed are part of a long range goal to elucidate the biochemical mechanism which regulates the enzyme responsible for generating oxygen radicals in phagocytes, NADPH oxidase. Two new methods have been developed in this laboratory for studying this problem. The first allows the activation of NADPH oxidase to be studied in disrupted cells. Dormant oxidase present in the membranes from unstimulated human neutrophils can be activated with arachidonic acid provided that a previously unrecognized cytosolic factor is also present. In the second method, membranes from unstimulated cells can be solubilized in such a way that they retain their ability to be activated by arachidonate and cytosolic factor. Since all of the components necessary for NADPH oxidase activation in the cell-free system can now be rendered soluble by these two methodologies, the major goal of this research grant will be to purify an characterize the cytosolic and membrane components required for NADPH oxidase activation. To accomplish this overall objective, four specific aims have been identified: 1) to purify the cytosolic factor and then raise both polyclonal and monoclonal antibodies to the purified material; 2) to determine the identity of the cytoplasmic factor and the mechanism by which it participates in the activation of NADPH oxidase; 3) to determine the membrane components required for the activation of NADPH oxidase as well as its catalytic activity; and 4) to identify the molecular lesions in the three major genetic forms of chronic granulomatous disease. These studies might ultimately lead to new pharmacological methods for controlling oxygen radical-mediated tissue damage as well as to an improved understanding of the pathophysiology of immune disorders like CGD.
von Löhneysen, Katharina; Noack, Deborah; Wood, Malcolm R et al. (2010) Structural insights into Nox4 and Nox2: motifs involved in function and cellular localization. Mol Cell Biol 30:961-75 |
Luxen, Sylvia; Noack, Deborah; Frausto, Monika et al. (2009) Heterodimerization controls localization of Duox-DuoxA NADPH oxidases in airway cells. J Cell Sci 122:1238-47 |
Lehmann, Mandy; Noack, Deborah; Wood, Malcolm et al. (2009) Lung epithelial injury by B. anthracis lethal toxin is caused by MKK-dependent loss of cytoskeletal integrity. PLoS One 4:e4755 |
von Lohneysen, Katharina; Noack, Deborah; Jesaitis, Algirdas J et al. (2008) Mutational analysis reveals distinct features of the Nox4-p22 phox complex. J Biol Chem 283:35273-82 |
Pacquelet, Sandrine; Lehmann, Mandy; Luxen, Sylvia et al. (2008) Inhibitory action of NoxA1 on dual oxidase activity in airway cells. J Biol Chem 283:24649-58 |
Maroto, B; Ye, M B; von Lohneysen, K et al. (2008) P21-activated kinase is required for mitotic progression and regulates Plk1. Oncogene 27:4900-8 |
Luxen, Sylvia; Belinsky, Steven A; Knaus, Ulla G (2008) Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res 68:1037-45 |
Zhu, Yanmin; Marchal, Christophe C; Casbon, Amy-Jo et al. (2006) Deletion mutagenesis of p22phox subunit of flavocytochrome b558: identification of regions critical for gp91phox maturation and NADPH oxidase activity. J Biol Chem 281:30336-46 |
Zhu, Hao; Larade, Kevin; Jackson, Timothy A et al. (2004) NCB5OR is a novel soluble NAD(P)H reductase localized in the endoplasmic reticulum. J Biol Chem 279:30316-25 |
Heyworth, Paul G; Cross, Andrew R; Curnutte, John T (2003) Chronic granulomatous disease. Curr Opin Immunol 15:578-84 |
Showing the most recent 10 out of 100 publications